Wednesday, 14 October 2026European Markets

FLEX LNG And 1 Other Stocks Have Very High Payout Ratio

Loading stream...

(vianews) - flex lng (flng.ol), axa (cs.pa), () are the highest payout ratio stocks on this list.

here's the data we've collected of stocks with a high payout ratio at the moment. the payout ratio in itself isn't a guarantee of a future good investment but it's an indicator of whether dividends are being paid and how the company chooses to issue them.

when researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.

1. flex lng (flng.ol)

112.36% payout ratio

earnings per share

as for profitability, flex lng has a trailing twelve months eps of kr24.15.

pe ratio

flex lng has a trailing twelve months price to earnings ratio of 11.44. meaning, the purchaser of the share is investing kr11.44 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.13%.

revenue growth

year-on-year quarterly revenue growth grew by 3.1%, now sitting on 368.39m for the twelve trailing months.

earnings before interest, taxes, depreciation, and amortization

flex lng's ebitda is 88.24.

moving average

flex lng's worth is way under its 50-day moving average of kr322.15 and way under its 200-day moving average of kr335.96.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on aug 30, 2023, the estimated forward annual dividend rate is 31.6 and the estimated forward annual dividend yield is 9.87%.

more news about flex lng.

2. axa (cs.pa)

59.03% payout ratio

earnings per share

as for profitability, axa has a trailing twelve months eps of €3.23.

pe ratio

axa has a trailing twelve months price to earnings ratio of 10.91. meaning, the purchaser of the share is investing €10.91 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.77%.

moving average

axa's worth is higher than its 50-day moving average of €32.05 and way higher than its 200-day moving average of €31.29.

more news about axa.

1. 1 (1)

1% payout ratio

1

earnings per share

as for profitability, 1 has a trailing twelve months eps of €1.

pe ratio

1 has a trailing twelve months price to earnings ratio of 1. meaning, the purchaser of the share is investing €1 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1%.

earnings before interest, taxes, depreciation, and amortization

1's ebitda is 1.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 1's stock is considered to be overbought (>=80).

revenue growth

year-on-year quarterly revenue growth grew by 1%, now sitting on 1 for the twelve trailing months.

growth estimates quarters

the company's growth estimates for the present quarter and the next is 1% and 1%, respectively.

more news about 1.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com